Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Rallybio Corporaton (RLYB)

Rallybio Corporaton (RLYB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Stock Index Futures are Higher after Wholesale Prices Increased Less Than Expected in March

June S&P 500 E-Mini futures (ESM24) are up 0.02%, and June Nasdaq 100 E-Mini futures (NQM24) are up 0.17%% this morning, after the release of the PPI data.

ESM24 : 5,471.89s (-0.09%)
NQM24 : 19,747.29s (-0.08%)
DECK : 180.74 (+2.48%)
MCHP : 66.41 (+1.98%)
ADI : 214.42 (+1.62%)
MNDY : 276.31 (+6.21%)
NVDA : 146.18 (+0.20%)
JPM : 244.94 (+1.73%)
WFC : 75.72 (+2.91%)
C : 69.38 (+1.61%)
GLE.FP : 26.640 (+0.38%)
RLYB : 0.9940 (-0.01%)
Rallybio to Present at the JMP Securities 2023 Life Sciences Conference

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases,...

RLYB : 0.9940 (-0.01%)
Rallybio Announces Clinical Proof-of-Concept Results for RLYB211, an Anti-HPA-1a Polyclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT), Published in the Journal of Thrombosis and Haemostasis

Rallybio Corporation (Nasdaq: RLYB) today announced publication of Phase 1 / 2 proof-of-concept results for RLYB211, a polyclonal anti-HPA-1a antibody derived from human plasma for the prevention of FNAIT....

RLYB : 0.9940 (-0.01%)
Rallybio Announces Acceptance of Abstract for RLYB212 at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH)

Rallybio Corporation (Nasdaq: RLYB) today announced that an abstract for RLYB212 reporting results from the Phase 1b proof-of-concept study has been accepted for presentation at the 31 st Congress of...

RLYB : 0.9940 (-0.01%)
Rallybio Reports Fourth Quarter and Full Year 2022 Financial Results

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases,...

RLYB : 0.9940 (-0.01%)
Rallybio Announces Proof-of-Concept Achieved for RLYB212, a Novel Monoclonal anti-HPA-1a Antibody to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia

Rallybio Corporation (Nasdaq: RLYB) today announced that clinical proof-of-concept has been achieved in a Phase 1b study for RLYB212, an anti-HPA-1a monoclonal antibody for the prevention of fetal and...

RLYB : 0.9940 (-0.01%)
Rallybio to Present at Upcoming Investor Conferences in March

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases,...

RLYB : 0.9940 (-0.01%)
EyePoint and Rallybio Announce Research Collaboration to Evaluate Rallybio’s Inhibitor of Complement Component 5 (C5) and EyePoint’s Proprietary Durasert® Technology for Sustained Intraocular Delivery in Geographic Atrophy

EyePoint Pharmaceuticals, Inc., a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, and Rallybio Corporation (NASDAQ: RLYB),...

RLYB : 0.9940 (-0.01%)
EYPT : 8.70 (-2.79%)
Rallybio Announces Appointment of Jonathan I. Lieber as Chief Financial Officer

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases,...

RLYB : 0.9940 (-0.01%)
Rallybio Highlights Portfolio Advances and Outlines Expected Milestones in 2023

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases,...

RLYB : 0.9940 (-0.01%)

Barchart Exclusives

ELF’s Unusual Options Activity Is a Thing of Questionable Beauty
E.L.F. Beauty’s options volume on Wednesday was 7x the 30-day average. The affordable makeup and skincare company’s unusual options activity stood out as one investor questioned its revenues. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar